Common cardiovascular diseases include rheumatic heart disease, hypertensive heart disease, ischemic heart disease, cerebrovascular heart disease, and inflammatory heart disease. Heart failure, angina, and hypertrophy are all major complications of hypertensive heart disease. These complications are caused by high blood pressure in the arteries and muscles of the heart, which causes constriction of the arteries as well as swelling and enlargement of the heart. Rising prevalence of heart illnesses, as well as an increasing elderly population and lifestyle-related disorders are major factors propelling the global cardiovascular drug market growth.
For Requesting a Sample Copy of This Report, Please Visit @
https://www.coherentmarketinsights.com/insight/request-sample/1167
To fulfill the needs of the growing population affected by cardiovascular diseases, medicines for treatment and prevention are essential. Growing number of diabetes patients is also expected to drive the global cardiovascular drugs market growth over the forecast period. According to the American Diabetes Association, 30.3 million had diabetes in 2015, accounting for 9.4 % of the Total Population in the U.S.
Manufacturers in the market are focusing on new product releases as well as mergers and acquisitions, which is propelling the global cardiovascular drugs market growth. However, the strict drug approval process and the adverse effects of several cardiovascular drugs are hindering the global cardiovascular drugs market growth during the forecast period.
Furthermore, the patent expiration of several branded drugs is expected to have a negative impact on the global cardiovascular drugs market’s revenue growth.
According to the American Heart Association (AHA), around 17.3 million people died due to cardiovascular diseases globally in 2013, accounting for 31% of all deaths. By 2030, the global figure is expected to expand to 23.6 million. The worldwide burden of cardiovascular diseases was US$ 863 billion in 2010, and by 2030, it is expected to increase to US$ 1044 billion. Every day, around 2,200 U.S. citizens die as a result of cardiovascular diseases, which equates to one fatality every 40 seconds.
Request a PDF Brochure with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-pdf/1167
Coherent Market Insights’ regional segmentation of the cardiovascular drugs market include North America, Latin America, Europe, Asia Pacific, Africa, and the Middle East. The global cardiovascular drugs market is oligopolistic, with a few companies controlling the majority of the market. In order to maintain their market position, major market players employ a variety of methods such as new product releases and collaborations.
For instance, in December 2017, Medicure Inc., a Canadian pharmaceutical company, acquired a seven-year exclusive license to market and sell a cardiovascular drug for the treatment of primary hyperlipidemia or mixed dyslipidemia in the U.S. and its territories through its subsidiary Medicure International Inc. Sun Pharmaceutical Industries’ subsidiary in the U.S. obtained approval from the U.S. Food and Drug Administration (FDA) in October 2017 to market a generic version of its Coreg CR. Coreg CR is used to diagnose a range of heart diseases, such as high blood pressure and heart failure. Cardurion Pharmaceuticals and Takeda Pharmaceutical Company Limited announced a collaboration in August 2017 to develop next-generation medicines for the treatment of cardiovascular diseases and heart failure.
Key players contributing to the global cardiovascular drugs market include Eli Lilly and Company, Novartis AG., Otsuka Holdings Co., Ltd., Bayer AG., Takeda Pharmaceutical Company Ltd, AstraZeneca Plc, Abbott Laboratories, Johnson & Johnson, Merck and Co. Inc., Gilead Sciences Inc., Bristol Myers Squibb Company, Pfizer Inc., and Sun Pharma Industries.
Reasons to Purchase this Report
• Current and future of global Cardiovascular Drugs market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
Table of Content
Global Cardiovascular Drugs Market Research Report
Section 1: Global Cardiovascular Drugs Industry Overview
Section 2: Global Economic Impact on Cardiovascular Drugs Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Cardiovascular Drugs Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837